RE:RE:RE:RE:RE:RE:RE:RE:Not Worried About SP... Guess that they are limited as to where they initially trial Rutherrin by a long-term research association with Princess Margaret/UHN and the Ontario grant.
If it`s GBM it seems that Lilge Betz Cassidy and Co.have optimised light activation of the compound to their satisfaction in respect of interstitial treatment but there are a lot of variables here including - tantalisingly - the potential use of trans-cranial x-ray as well as multiple adjuvants (cannabinoid, vaccine etc.) so definition of the Clinical Protocol is likely still ongoing.
We’ve been told little of progress on the science side since the OSC debacle. Have held other biotechs where hope and share price have been sustained for many years with a lot less ammo than the Management have here.
Can only hope that as soon as they are ready they are able to press the button but in the meantime Shareholders deserve more than this.